On September 9, 2026, Gan & Lee Pharmaceuticals said the first participant was dosed in a first-in-human Phase 1 study of GZC8072 tablets. The English PR Newswire release and the same-day PR Newswire Asia copy call the candidate an ultra-long-acting oral peptide GLP-1 receptor agonist designed for once-weekly administration.
A first dose starts human dosing. It is not weight-loss efficacy. It is not a type 2 diabetes result. It is not FDA or NMPA marketing approval.
GZC8072 is not ASC30, Ascletis's once-daily oral small-molecule GLP-1 already in Phase 3 AURORA. It is not orforglipron (Foundayo), an oral small-molecule GLP-1. It is not ASC36, an oral amylin peptide. It is not bofanglutide (GZR18), Gan & Lee's biweekly injectable GLP-1, or that company's separate historical GZR18 tablet program.
This is the 8:07 Industry News for 13 September 2026. The same-day vosoritide CANOPY-HCH-3 Research Roundup stays as written.
What happened
Chinese market copy moved first. A Shanghai Stock Exchange-style company flash (announcement 2026-071, stock 603087, board date 8 September 2026) said the wholly owned subsidiary Gan & Lee Pharmaceutical Shandong Co., Ltd. had recently completed first-subject dosing in a China Phase I study of GZC8072 tablets. China Securities Journal reprinted that filing. Same-week wires on 7 September used the same "recently completed" first-dose sentence.
The September 9 English release is the company primary used here for the first-in-human milestone. It names China registry ID CTR20263271. It describes a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase 1. Planned enrollment is 112 participants, assigned to GZC8072 tablets or matching placebo. Single ascending dose (SAD) is in healthy adults. Multiple ascending dose (MAD) is in people with overweight or obesity.
GZC8072 is being developed for type 2 diabetes mellitus (T2DM) and for weight management in obesity or overweight. Those are intended indications. They are not approved uses.
ClinicalTrials.gov NCT07784699, queried 13 September 2026, is the matching English registry record. Protocol ID GZC8072-BWM-101. Sponsor: Gan & Lee Pharmaceuticals. The trial is conducted in China. The listed site is Beijing Shijitan Hospital. Estimated enrollment is 112. Ages are 18 to 55. Primary completion and completion are both listed as 18 August 2027 (estimated). hasResults is false.
The registry overall status was still NOT_YET_RECRUITING. The last update posted is 25 August 2026. The start date is listed as 4 September 2026 (estimated). A company first-dose announcement can land while ClinicalTrials.gov still shows NOT_YET_RECRUITING. That is treated here as possible registry lag. This article does not invent a new NCT status.
What GZC8072 is
The English release calls GZC8072 a novel ultra-long-acting oral peptide GLP-1 RA independently developed by Gan & Lee based on native GLP-1 and designed for once-weekly administration. The company's 7 September site note (body dateline Beijing, 3 September 2026) adds Class 1 innovative, biased, ultra-long-acting language and independent intellectual-property language. Those are company labels. This article does not invent receptor-bias data.
Two company platforms are named in both the English release and the Chinese flash: NovaPeptide (long-acting peptide development and manufacturing, in the company's wording) and SupOraTide (oral peptide delivery). Combined use is said to give enhanced intrinsic activity, a prolonged pharmacokinetic half-life, and improved oral bioavailability that could support once-weekly oral dosing. Those sentences are company platform claims. They are not human pharmacokinetic results.
The Chinese first-dose filing also states, as a company claim, that no GLP-1 once-weekly oral formulation has been approved worldwide yet. That sentence is the company's competitive claim. It is not a PeptidePrices landscape review. Daily oral GLP-1 products already exist. A weekly oral peptide claim is a different design target. Approval of a daily oral product is not approval of GZC8072.
A research-vendor vial labeled "oral GLP-1" or "weekly peptide" is not the investigational tablet. A COA check can test whether a certificate names a real lab. It cannot turn a catalog chemical into Gan & Lee's Phase 1 product.
| Asset | What it is | Cited status |
|---|---|---|
| GZC8072 tablets | Oral peptide GLP-1 RA, once-weekly design (company) | FIH Phase 1 first dose announced. China study. CTR20263271 / NCT07784699. |
| Bofanglutide (GZR18) injection | Biweekly injectable GLP-1 RA (company pipeline context) | Separate injectable program. Not this tablet. |
| Historical GZR18 tablet | Separate oral GZR18 tablet program (company history) | Not GZC8072. Do not merge the codes. |
| Ludefen (GZR4) | Ultra-long-acting weekly insulin (company pipeline context) | Insulin, not a GLP-1. |
| ASC30 | Once-daily oral small-molecule GLP-1 | Global Phase 3 AURORA. Different sponsor, different molecule class. |
| Orforglipron (Foundayo) | Oral small-molecule GLP-1 | Different molecule class. Already covered on this site. |
| ASC36 oral tablet | Oral amylin receptor peptide | Separate U.S. Phase I start. Not a GLP-1. |
Trial design: SAD, MAD, 112 planned
The September 9 English release and NCT07784699 agree on the skeleton. They do not publish milligrams.
| Item | Company English release (9 Sept 2026) | NCT07784699 (queried 13 Sept 2026) |
|---|---|---|
| IDs | CTR20263271 | NCT07784699 / GZC8072-BWM-101 |
| Design | Multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase 1 | Interventional Phase 1, randomized, parallel, double-masked (participant and investigator) |
| Location | China Phase I (Chinese flash). English release does not add a U.S. site. | Conducted in China. Beijing Shijitan Hospital listed. |
| N | 112 planned | 112 estimated |
| Assignment | GZC8072 tablets or matching placebo | Same two arms |
| SAD | Healthy adult participants | Safety, tolerability, and PK of single oral doses. BMI 19.0 to 28.0 kg/m2. Weight at least 54.0 kg (men) or 50.0 kg (women). Ages 18 to 55. |
| MAD | Participants with overweight or obesity | Safety, tolerability, PK, and PD of multiple oral doses. BMI 24 to 35 kg/m2. Ages 18 to 55. |
| Primary named | Safety and tolerability | Incidence of adverse events and serious adverse events. Immunogenicity (anti-drug antibodies and neutralizing antibodies). SAD: baseline to Day 36. MAD: baseline to Day 57. |
| Secondaries named | Not itemized in the English release | PK: Cmax, AUC0-t, AUC0-inf, Tmax, half-life, CL/F, Vd, and steady-state concentration terms. MAD PD: fasting weight, BMI, waist circumference, fasting plasma glucose, fasting insulin. |
| Status | First participant dosed | NOT_YET_RECRUITING. Start 4 September 2026 estimated. Last update 25 August 2026. No results posted. |
| FDA-regulated drug flag | Not stated | isFdaRegulatedDrug false |
Do not read the MAD fasting-weight, BMI, and waist fields as a Phase 3 obesity primary. They are Phase 1 pharmacodynamic measures on a Day 57 window. The English release's stated Phase 1 job is safety and tolerability.
No milligram ladder appears in the English release, the Chinese first-dose filing, the company T2DM-approval page, or NCT07784699. This article does not invent one. GZC8072 is not approved for human use. That does not make an unpublished tablet strength an approved dose.
NCT exclusion language lists allergy, intolerance, or hypersensitivity to GLP-1 receptor agonists, SNAC, C10, or other investigational-product excipients. That is eligibility text. It is not a published formulation table, and it is not proof that GZC8072 uses the same absorption-enhancer recipe as another oral GLP-1.
| Setting | What is published | What is not |
|---|---|---|
| Route | Oral tablets | Food-effect results |
| Schedule intent | Once-weekly design (company) | A public milligram-by-week ladder |
| SAD window | Safety, tolerability, PK. Registry follow-up to Day 36 | Human bioavailability percentage |
| MAD window | Safety, tolerability, PK, PD. Registry follow-up to Day 57 | A weight-loss efficacy primary |
| Comparator | Matching placebo | An active oral GLP-1 control |
NMPA clinical-trial approval is not marketing approval
The company page dated 7 September 2026 says GZC8072 tablets received NMPA clinical-trial approval for T2DM. The body dateline is Beijing, 3 September 2026. The company calls this the second indication after obesity or overweight. The same page says global development has entered Phase I.
That is authorization to run clinical trials in the named indication. It is not an NMPA marketing approval. The page's own disclaimer says the note is an R&D update, not drug promotion, medical advice, or a performance commitment, and that complete later outcomes should be read from the same-day Shanghai Stock Exchange announcement.
The 8 September first-dose filing lists NMPA Drug Clinical Trial Approval Notices issued in August and September 2026 for obesity or overweight and for T2DM. Notice numbers in that filing: 2026LP02574, 2026LP02575, 2026LP02576, 2026LP02577, 2026LP02690, 2026LP02691, 2026LP02692, and 2026LP02693. Those numbers are cited from the company flash. This article does not invent extra notice text.
As of 30 June 2026, the same flash says Gan & Lee had spent 66.3326 million RMB on the GZC8072 tablet project. That is a company-disclosed cumulative research-and-development figure. It is not an efficacy result.
The T2DM-approval page also says preclinical studies showed favorable pharmacodynamic and pharmacokinetic profiles and a good safety profile. That sentence is a company preclinical claim. It is not a human result.
Pipeline context, not this week's result
The English release places GZC8072 next to two other Gan & Lee programs: biweekly injectable bofanglutide (GZR18) and ultra-long-acting weekly insulin Ludefen (GZR4). Those names are pipeline context. They do not transfer injection or insulin data onto this tablet.
Keep the codes apart. GZR18 is the injectable bofanglutide program, and the company previously ran a separate oral GZR18 tablet effort. GZC8072 is the once-weekly oral peptide named in this first-dose package. Sharing a sponsor is not sharing a molecule.
ASC30 remains the small-molecule oral GLP-1 Phase 3 record on this site. ASC36 remains the oral amylin Phase I start. Orforglipron remains the oral small-molecule explainer. Retatrutide's FDA timeline is a different injectable peptide. None of those pages is rewritten here.
Live semaglutide and tirzepatide listings are price-and-vendor views of different products. They are not GZC8072 storefronts.
What this does not mean / what did not change
- It is not human efficacy. No SAD or MAD safety table, pharmacokinetic table, or weight change is in the September 7 to 9 package.
- It is not FDA or NMPA marketing approval. NMPA notices in this record are clinical-trial authorizations. The English release is a first-dose operational milestone.
- Phase 1 first dose is not a weight-loss claim. MAD fasting-weight and BMI fields are registry pharmacodynamic endpoints, not a completed obesity trial.
- Preclinical PD, PK, and safety sentences are not human results. The company said those preclinical profiles were favorable. That is a sponsor claim.
- NovaPeptide and SupOraTide claims are platform claims. They do not prove once-weekly human exposure.
- The company's "no weekly oral GLP-1 approved worldwide" sentence is a company claim. It is not a full competitive monograph, and it does not erase daily oral GLP-1 products.
- GZC8072 is not GZR18 / bofanglutide. Injectable GZR18 and the historical GZR18 tablet are separate programs.
- GZC8072 is not ASC30, orforglipron, or ASC36. Small-molecule oral GLP-1s and an oral amylin peptide are different assets.
- ClinicalTrials.gov still showed NOT_YET_RECRUITING on the 13 September query. This article does not overwrite that field.
- This is not medical advice, and it is not a consumer dosing protocol.
GZC8072's unapproved status did not change on 13 September 2026. No PeptidePrices research page was created. NCT07784699 did not gain a posted results module in the query used here.
What to watch
- A ClinicalTrials.gov status refresh. Watch whether NOT_YET_RECRUITING becomes recruiting or active, and whether the estimated start is replaced by an actual start.
- A China registry detail page that matches CTR20263271. The English release cites that ID. This article does not invent a missing public HTML record.
- First-in-human safety, tolerability, immunogenicity, and PK. Those are the Phase 1 questions. Day 36 and Day 57 windows are follow-up fields, not efficacy readouts.
- Whether a milligram ladder is disclosed. None is published in the sources used here.
- How later copy treats the weekly-oral claim. Keep it as a company design target until a human half-life and bioavailability table exists.
- T2DM versus overweight or obesity protocols. The NMPA T2DM notice expands the clinical-trial scope. It does not create a second completed study in this package.
FAQs
Did Gan & Lee prove that once-weekly oral GZC8072 causes weight loss?
No. The September 7 to 9 announcements are a first-in-human dose in a China Phase 1 safety study. They are not an efficacy readout.
Is GZC8072 approved by FDA or NMPA for diabetes or obesity?
No. NMPA notices cited here authorize clinical trials. They are not marketing approvals. GZC8072 remains investigational.
Is GZC8072 the same drug as ASC30 or orforglipron?
No. GZC8072 is an investigational oral peptide GLP-1. ASC30 and orforglipron are oral small-molecule GLP-1 receptor agonists.
Is GZC8072 the same drug as GZR18 / bofanglutide?
No. Bofanglutide (GZR18) is Gan & Lee's biweekly injectable GLP-1. The company also had a separate historical GZR18 tablet program. GZC8072 is the once-weekly oral peptide in this first-dose package.
Why does ClinicalTrials.gov still say NOT_YET_RECRUITING?
NCT07784699, queried 13 September 2026, still showed NOT_YET_RECRUITING, with a last update posted 25 August 2026 and an estimated start of 4 September 2026. The company said the first participant had been dosed. Treat that gap as possible registry lag. Do not invent a new status.
What dose was used?
The fetched company and registry texts do not publish milligrams. GZC8072 is not approved for human use. That does not make an unpublished tablet strength an approved dose.
This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions. GZC8072 is an investigational oral peptide GLP-1 receptor agonist in a company-reported Phase 1 program. Nothing here is a dosing protocol, an availability claim, or a recommendation to obtain an unapproved product.
Continue your research
- ASC30 oral GLP-1 Phase 3 AURORA
- ASC36 oral amylin peptide Phase 1
- Orforglipron, the first oral GLP-1 pill
- Is retatrutide FDA approved?
- Semaglutide price comparison
- How to verify a peptide COA
- COA Authenticity Checker
Sources
- Gan & Lee Pharmaceuticals. First participant dosed in first-in-human Phase 1 study of GZC8072, a novel ultra-long-acting once-weekly oral peptide GLP-1 RA. PR Newswire. 9 September 2026
- Same release, PR Newswire Asia. 9 September 2026
- ClinicalTrials.gov NCT07784699. Phase 1 SAD in healthy adults and MAD in overweight or obesity for GZC8072 tablets
- Gan & Lee Pharmaceuticals. Oral peptide GLP-1 RA weekly dosing GZC8072 tablet: clinical trial approval for type 2 diabetes indication. Company site dated 7 September 2026 (body dateline 3 September 2026)
- Gan & Lee Pharmaceuticals. Announcement 2026-071 on first-subject dosing in the GZC8072 tablet Phase I trial. Board date 8 September 2026 (hosted copy)
- China Securities Journal reprint of the GZC8072 first-dose announcement. 8 September 2026